Argentina Multi Cancer Early Detection Market Size & Outlook
The multi cancer early detection market in Argentina is expected to reach a projected revenue of US$ 23.6 million by 2030. A compound annual growth rate of 17.8% is expected of Argentina multi cancer early detection market from 2025 to 2030.
Every answer starts with GVR research, and every figure is cited.Explore Prism AI ↗
Argentina multi cancer early detection market highlights
The Argentina multi cancer early detection market generated a revenue of USD 8.9 million in 2024 and is expected to reach USD 23.6 million by 2030.
The Argentina market is expected to grow at a CAGR of 17.8% from 2025 to 2030.
In terms of segment, gene panel, ldt & others was the largest revenue generating type in 2024.
Liquid Biopsy is the most lucrative type segment registering the fastest growth during the forecast period.
Multi cancer early detection market data book summary
Market revenue in 2024
USD 8.9 million
Market revenue in 2030
USD 23.6 million
Growth rate
17.8% (CAGR from 2025 to 2030)
Largest segment
Gene panel, ldt & others
Fastest growing segment
Liquid Biopsy
Historical data
2018 - 2023
Base year
2024
Forecast period
2025 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Liquid Biopsy, Gene Panel, LDT & Others
Key market players worldwide
Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta
Other key industry trends
In terms of revenue, Argentina accounted for 0.8% of the global multi cancer early detection market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Latin America, Brazil multi cancer early detection market is projected to lead the regional market in terms of revenue in 2030.
Argentina is the fastest growing regional market in Latin America and is projected to reach USD 23.6 million by 2030.
Constant developments by market players, such as geographic expansion and new product launches, have contributed to Argentina’s market growth. For instance, Amoy Diagnostics Co Ltd. entered into a collaboration agreement with Merck KGaA to bring liquid biopsy RAS biomarker tests to Argentina, Mexico, India, and Brazil.
Initially, the test would be made available for research use only until it gets regulatory authorization from the respective countries. In addition, the country has a higher burden of cancer and the rising prevalence of cancer among the population is propelling the demand for adoption of cancer screening tests.
Moreover, Latin America has seen a steady rise in the number of oncologists, especially in Brazil and Argentina, as well as awareness of the region's chronic scarcity of cancer specialists. To enhance and promote the initiative's activities in the region, a regional hub for Latin America has been established at the National Cancer Institute of Argentina (Instituto Nacional del Cancer de Argentina) in Buenos Aires.
Argentina Multi Cancer Early Detection Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Multi Cancer Early Detection Market Outlook will help companies and investors design strategic landscapes.
Gene Panel, Ldt & Others was the largest segment with a revenue share of 110.11% in 2024.
Horizon Databook has segmented the Argentina multi cancer early detection market based on liquid biopsy, gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
Constant developments by market players, such as geographic expansion and new product launches, have contributed to Argentina’s market growth. For instance, Amoy Diagnostics Co Ltd. entered into a collaboration agreement with Merck KGaA to bring liquid biopsy RAS biomarker tests to Argentina, Mexico, India, and Brazil.
Initially, the test would be made available for research use only until it gets regulatory authorization from the respective countries. In addition, the country has a higher burden of cancer and the rising prevalence of cancer among the population is propelling the demand for adoption of cancer screening tests.
Moreover, Latin America has seen a steady rise in the number of oncologists, especially in Brazil and Argentina, as well as awareness of the region's chronic scarcity of cancer specialists. To enhance and promote the initiative's activities in the region, a regional hub for Latin America has been established at the National Cancer Institute of Argentina (Instituto Nacional del Cancer de Argentina) in Buenos Aires.
Argentina Multi Cancer Early Detection Market Type Outlook (Revenue, USD Million , 2018-2030)
Liquid Biopsy
Gene Panel, LDT & Others
Argentina Multi Cancer Early Detection Market End Use Outlook (Revenue, USD Million , 2018-2030)
Hospitals
Diagnostic Laboratories
Others
Reasons to subscribe to Multi Cancer Early Detection Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Multi Cancer Early Detection Market Outlook databook
Our clientele includes a mix of Multi Cancer Early Detection Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina Multi Cancer Early Detection Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Argentina Multi Cancer Early Detection Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Argentina Multi Cancer Early Detection Market, 2018-2030 (US$M)